Improving engineered T-cell therapy for pancreatic cancer
Official title: Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
Funded at University of Minnesota · NIH-11211991 · Data updated 2026-11-12
Engineered T cells that target the protein mesothelin are being developed to shrink tumors and change the tumor environment for people with pancreatic cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 16, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $91,282 |
| NIH project number | 3R01CA255039-05S1 |
| Project ID | NIH-11211991 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with advanced pancreatic ductal adenocarcinoma whose tumors express mesothelin and who are medically eligible for cell-based immunotherapy trials.
✕Less likely to help
Patients whose tumors lack mesothelin, who are too frail for cell therapy, or who have active autoimmune disease may not benefit from this approach.
What this research studies
Researchers are creating T cells engineered to carry a receptor that recognizes mesothelin, a protein commonly found on pancreatic tumor cells. They are testing these T cells in aggressive animal models that mimic human pancreatic ductal adenocarcinoma to see how well the cells kill cancer and break down the surrounding fibrous stroma. The team measures tumor responses, how the engineered T cells accumulate in tumors, and changes in immune cells in the tumor microenvironment. Findings are intended to guide future clinical testing of this approach in patients.
Why it matters
Potential benefit: If successful, this approach could make immunotherapy work better in pancreatic cancer, reduce tumor-supporting stroma, and potentially extend survival.
How similar studies have gone: T-cell therapies targeting tumor antigens have succeeded in some cancers and mesothelin-targeting approaches have shown promise, but pancreatic cancer remains difficult and this engineered strategy is relatively new with encouraging preclinical results.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Stromnes, Ingunn Margarete — University of Minnesota
- Study coordinator: Stromnes, Ingunn Margarete
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.